The document describes a business model canvas for a company targeting recombinant hemagglutinin (HA) for pandemic and seasonal influenza. Key elements include relying on gene synthesis companies, CMOs for manufacturing, and pursuing regulatory approval, speed, cost-effectiveness, and scalability. Distribution would be through government agencies and pharmaceutical companies. Revenue streams include capital investments, manufacturing contracts, and licensing royalties. The goal is to secure long-term contracts with government agencies and vaccine manufacturers in both the US and abroad.

1. The Business Model Canvas Target Product – Recombinant hemagglutinin (HA)
for pandemic and seasonal influenza
Tobacco Suppliers R&D Speed Long-Term U.S. Government
Gene Synthesis Manufacturing Cost-Effectiveness Contracts with - CDC
Companies Regulatory Approval Robustness Government and - HHS BARDA
CMOs Licensing Scalability Vaccine - DOD DARPA
- Purification Marketing Safety Manufacturers Foreign Governments
- Fill & Finish Ease of Customization NGOs
- Packaging U.S. Supply Vaccine Manufacturers
- QA/QC -Established and
CROs Emerging Biotech
- Clinical Trials
FDA IP – Patents, Trade
Secret
Manufacturing Facility
Distribution through
Government and
Pharma Companies
Capital Investments Contract Manufacturing
Manufacturing Costs Fully Integrated Manufacturing (Sales)
Licensing Costs Licensing (Royalties)
Marketing

2. The Business Model Canvas Target Product – glucocerebrosidase
Conferences
Tobacco Suppliers R&D Speed Long-Term U.S. Government
Gene Synthesis Manufacturing Cost-Effectiveness Contracts with - CDC
Companies Regulatory Approval Robustness Government and - HHS BARDA
CMOs Licensing Scalability Vaccine - DOD DARPA
- Purification Marketing Safety Manufacturers Foreign Governments
- Fill & Finish Ease of Customization Pharma NGOs
- Packaging U.S. Supply Wholesalers Vaccine Manufacturers
- QA/QC Improved Product Pharma Companies
CROs Quality - Established and
- Clinical Trials Emerging Biotech
FDA IP – Patents, Trade
Secret
Manufacturing Facility
Distribution through
Government and
Pharma Companies
Capital Investments Contract Manufacturing
Manufacturing Costs Fully Integrated Manufacturing (Sales)
Licensing Costs Licensing for Specific Targetsor Specific
Marketing Worldwide Regions (Royalties)

4. The Business Model Canvas: ver 0.0
Privacy Creating Increased educational
advocacy Privacy-
awareness privacy
groups trust concerned
customers
Building trust who use LBS
LBS App
Providers
Technology
Own website
Bundling with
LBS apps
Developing
App revenue (direct or shared)
costs
Marketing
costs

5. The Business Model Canvas: ver 0.1
Privacy Creating Increased educational
advocacy awareness Privacy-
privacy
groups trust concerned
customers
Building trust
LBS App No loss of who use LBS
Providers service
quality
Smart phone
users uneasy
about privacy
Technology
Own website
Bundling with
LBS apps
Developing
App revenue (direct or shared)
costs
Marketing
Subscription
costs